Enfusion Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	6.03	-7.65	-158.32	4.06	12.66
Depreciation & Amortization	16.87	11.7	3.98	2.29	1.16
Share-Based Compensation	7.46	24.99	289.8	0	0
Other Operating Activities	-4.72	-14.88	-135.78	-4.69	-1.51
Operating Cash Flow	25.63	14.16	-0.32	1.67	12.31
Operating Cash Flow Growth	81.08%	-	-	-86.47%	-
Capital Expenditures	-9.67	-7.93	-8.01	-5.07	-4.43
Investing Cash Flow	-9.67	-7.93	-8.01	-5.07	-4.43
Share Issuance / Repurchase	17.32	0	172.7	0	0
Debt Issued / Paid	-1.15	0	-100	70.74	27.61
Other Financing Activities	-59.25	-7.96	-13.85	-59.18	-35.15
Financing Cash Flow	-43.08	-7.96	58.85	11.56	-7.54
Exchange Rate Effect	0.18	-0.09	-0.09	-0.12	-0.09
Net Cash Flow	-26.94	-1.82	50.43	8.04	0.25
Free Cash Flow	15.96	6.23	-8.33	-3.4	7.88
Free Cash Flow Growth	156.43%	-	-	-	-
Free Cash Flow Margin	9.15%	4.14%	-7.46%	-4.28%	13.34%
Free Cash Flow Per Share	0.18	0.07	-0.10	-0.03	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).